Document is current

Article History

Received: 13 November 2025

Revised: 10 February 2026

Accepted: 10 February 2026

First Online: 18 February 2026

Declarations

:

: S.K., E.M., S.A.P., A.F., A.N., R.R.R., J.L.G., T.M., L.K.F., J.A.F., R.S., D.T.J., H.B., N.R.G-R., G.S.D., and W.K.K. report no disclosures relevant to the manuscript. D.O. receives research support from the Japan Science and Technology Agency and the Japan Society for the Promotion of Science. D.W.D receives research support from NIH. C.G.S. receives research support from the NIH. M.L.S. owns or has owned stock in medical-related companies, unrelated to the current work, within the past 36 months: Align Technology, Inc., Inovio Pharmaceuticals, Inc., Mesa Laboratories, Inc., Johnson and Johnson, LHC Group, Inc., Natus Medical Inc., and Varex Imaging Corporation. C.R.J. has consulted for Lily and serves on an independent data monitoring board for Roche and as a speaker for Eisai, but he receives no personal compensation from any commercial entity. He receives research support from NIH and the Alexander Family Alzheimer’s Disease Research Professorship of the Mayo Clinic. T.M. receives research support from National Institute of Health and Zander Family Foundation. V.K.R. receives research funding from the NIH and the Mayo Clinic Dorothy and Harry T. Mangurian Jr. Lewy Body Dementia Program and has provided educational content for Medscape, Expert Perspectives in Alzheimer’s Disease, Clinical Care Options, and Roche/ADLM; has received speaker and conference session honoraria from the American Academy of Neurology Institute; is PI for a clinical trial supported by the Alzheimer’s Association; is site Co-PI for the Alzheimer’s Clinical Trials Consortium; and is a site clinician for clinical trials supported by Eisai, the Alzheimer's Treatment and Research Institute at USC, and Transposon Therapeutics, Inc., unrelated to this work. E.K.St.L. has no disclosures related to this work. He has served as a Co-Investigator on K.K. research grant (DLB U01) and as a NAPS co-investigator. D.S.K. serves on a Data Safety Monitoring Board for the DIAN study, has served on a Data Safety Monitoring Board for a tau therapeutic for Biogen but received no personal compensation, is a site investigator in Biogen aducanumab trials, is an investigator in clinical trials sponsored by Lilly Pharmaceuticals and the University of Southern California, serves as a consultant for Samus Therapeutics, Roche, Magellan Health and Alzeca Biosciences but receives no personal compensation, and receives research support from the NIH. T.J.F. serves as a consultant for Acadia pharmaceuticals and receives funding from NIH and the Mayo Clinic Dorothy and Harry T. Mangurian Jr. Lewy Body Dementia Program. V.J.L. serves as a consultant for Bayer Schering Pharma, Piramal Life Sciences, Life Molecular Imaging, Eisai Inc., AVID Radiopharmaceuticals, and Merck Research and receives research support from GE Healthcare, Siemens Molecular Imaging, AVID Radiopharmaceuticals, and the NIH (NIA, NCI). R.C.P. serves as a consultant for Roche, Inc., Merck, Inc., Biogen, Inc., Eisai, Inc., Genentech, Inc., and Nestle, Inc., served on a DSMB for Genentech, receives royalties from Oxford University Press and UpToDate, and receives NIH funding. B.F.B. has served as an investigator for clinical trials sponsored by Alector, Cognition Therapeutics, EIP Pharma/Cervomed, and Transposon. He serves on the Scientific Advisory Board of the Tau Consortium, funded by the Rainwater Charitable Foundation. He receives research support from NIH, the Mayo Clinic Dorothy and Harry T. Mangurian Jr. Lewy Body Dementia Program, the Little Family Foundation, and the Ted Turner and Family Foundation. K.K. consults for Biogen, Eisai, and BioArctic with no personal compensation, received research support from Avid Radiopharmaceuticals and Eli Lilly, and receives funding from NIH and Alzheimer’s Drug Discovery Foundation.